The Amgen emblem is displayed outdoors Amgen headquarters on Might 17, 2023 in Thousand Oaks, California.
Mario Tama | Getty Photographs
The Federal Commerce Fee on Friday mentioned it has reached a deal with drug big Amgen to permit the corporate’s $27.8 billion buy of Horizon Therapeutics to maneuver ahead.
The 2 corporations now count on to shut the acquisition – Amgen’s largest ever – early within the fourth quarter of this 12 months, a spokesperson for Amgen mentioned.
The settlement resolves a lawsuit the FTC filed in Might looking for to dam the acquisition over issues it will enable Amgen to leverage its drug portfolio to stifle competitors within the pharmaceutical trade. The company this week briefly suspended that go well with, which allowed it to think about whether or not to settle the case.
However the settlement introduced Friday nonetheless imposes restrictions on Amgen to deal with key issues the FDA raised in its go well with.
The deal particularly prohibits Amgen from “bundling” two of Horizon’s blockbuster medication: thyroid eye illness remedy Tepezza and Krystexxa, a gout drugs.
That apply includes providing rebates or reductions on its present merchandise to stress insurers and pharmacy profit managers into favoring the Horizon merchandise.
Amgen may even must get approval from the FTC to amass any merchandise that deal with the identical illnesses as Tepezza and Krystexxa do. Amgen is required to hunt these signal offs from the company via 2032.
All different necessities can be efficient for 15 years after the settlement is finalized, in keeping with the FTC.
As a part of the deal, attorneys normal for California, Illinois, Minnesota, New York, Washington, and Wisconsin have additionally agreed to dismiss their federal fits looking for to dam the merger.
Shares of Horizon rose almost 3% in early morning buying and selling Friday. Amgen’s inventory edged up barely.
The spokesperson for Amgen mentioned the corporate has no “motive, capacity, or intention” to bundle Horizon’s two fast-growing medicines. The brand new settlement “could have no affect on Amgen’s enterprise,” the spokesperson added.
A Horizon spokesperson didn’t instantly reply to a request for remark.
Amgen first moved to purchase Horizon in December 2022 in an effort to achieve entry to the latter’s uncommon illness belongings, however buyout was fast to draw regulatory and political scrutiny for its potential antitrust points.
Sen. Elizabeth Warren, D-Mass., in a letter to FTC Chairwoman Lina Khan requested the regulator to “closely scrutinize” the acquisition and the then-pending merger of Indivior and Opian. She warned the offers might result in increased costs.
The FTC ultimately heeded Warren’s warnings and filed its lawsuit.
In a separate assertion Friday, Khan mentioned the company will “proceed to problem illegal practices that elevate drug costs, inhibit entry, stifle innovation, or in any other case damage sufferers.”
The FTC is at the moment reviewing Pfizer’s $43 billion acquisition of most cancers drug developer Seagen, one of many largest offers of this 12 months. The company began an in-depth investigation into the transaction in July.
The FTC, below Khan, has challenged a lot of high-profile mergers. However the company has struggled in court docket this 12 months, dropping instances to dam a Meta deal and Microsoft’s acquisition of Activision Blizzard.
